Chris Martin, DPhil, MBA
Chairman and Non Executive Director
Chris is a renowned biotech company founder, director and entrepreneur, and a pioneer and leader in the antibody-drug conjugate (ADC) space.
He was instrumental in co-founding ADC Therapeutics in 2012 and served as its CEO since inception until 2022. Under his leadership, ADC Therapeutics grew from a private biotech start-up to a New York Stock Exchange (NYSE) listed leader in the field of ADCs with products on the global market.
Earlier in his career he co-founded and was the CEO of Spirogen Ltd, an innovator of ADC payload technology, which was acquired by MedImmune, now a member of the AstraZeneca group. Prior to the acquisition, Chris led numerous Spirogen collaboration transactions, including agreements with Genentech and Seattle Genetics and post-acquisition he served for two years as VP Spirogen, AstraZeneca. He also co-founded and was the Chairman of Sciona, Inc. a provider of personalised gene-based health and nutrition analyses.
Alongside his role as Chairman of Myricx, he is also Chairman of the Board of Tokamak Energy Ltd, and Tagworks Pharmaceuticals BV, and a Director on the Board of Osivax SAS.
Chris is a Fellow of the Institution of Chemical Engineers and a Sainsbury Management Fellow, he holds a bachelor’s degree in chemical engineering from Aston University, a DPhil in Engineering Science from the University of Oxford, and an MBA from IMD Business School.
Michael Bauer, PhD
Non Executive Director
Michael is a Partner in the Venture Investments group at Novo Holdings.
He joined Novo Holdings in 2020. From 2006-2020, Michael was employed at Genmab in various positions with increasing responsibility; starting in Project Management taking daratumumab / DARZALEX® into the clinic. Between 2010-2018 he led Clinical Development and was part of the senior leadership team that repositioned and rebuilt the company into a global cancer and antibody powerhouse. From 2018 he led R&D Operations preparing the company for filing of its first own product.
Prior to Genmab, Michael worked as Associate at BankInvest Biomedical Venture and as Licensing Associate in Scientific Licensing at Novo Nordisk A/S, after having spent 7 years as Research Scientist at Novo Nordisk A/S covering areas such as endocrinology, metabolic disease, cancer and inflammation. Before joining the industry, Michael worked for 6 years at the Research Centre for Developmental Medicine & Biology at the University of Auckland, New Zealand, investigating causes and possible treatment modalities of intra-uterine growth restriction.
Michael earned a Masters (Dipl. Ing. agr.) in Agricultural Science from the University of Stuttgart-Hohenheim, Germany and a Ph.D. in Agricultural Science – summa cum laude – from the University of Göttingen, Germany.
Maina Bhaman, MBA
Non Executive Director
Maina Bhaman is a partner at Sofinnova Partners. She joined the firm in 2018 and has a long track record as a successful healthcare investor.
Prior to joining Sofinnova Partners, Maina was Director of Healthcare Investment at Touchstone Innovations (formerly Imperial Innovations) in London, UK, where she led and co-led investments in the UK.
Previously, she worked in the R&D teams of several UK and US biotech companies, including Celltech, Oxford Glyco Sciences, Chimeric Therapies and GeneMedicine.
Maina holds a B.S. from the University of Texas at Austin and an MBA from the Imperial Business School. Maina’s current investments include Sitryx Therapeutics, Cincor and Enyo Pharma.
Robin Carr, PhD
Chief Executive Officer
Robin joined Myricx in Nov 2019 as chief development officer and became CEO in August 2022.
Robin joined Myricx from GSK, where he held several research Exec roles (2007-2019), his final role was SVP Drug Design and Selection, with global responsibility for small molecule and biopharm discovery platforms. Robin served as a member of GSK’s Discovery Investment Board, Technology Investment Board and co-chaired the target selection committee.
Prior to GSK, Robin was VP of drug discovery at Astex Therapeutics (1999-2007), with responsibility for internal and partnered drug discovery programs.
Robin holds a chemistry degree from Imperial College London (1981) and completed his PhD studies in total synthesis at Northwestern University, Chicago (1984). Robin then returned to the UK to start his industrial research career at ICI agrochemicals before joining Glaxo in 1989 to focus on drug discovery.
Robin has co-authored and published 50 papers and patents and contributed to numerous discovery programs (cancer and respiratory) that have progressed into the clinic and two of which went on to become launched drugs.
Robin has a long-standing interest in novel drug discovery platforms that have the potential to reduce attrition rates and therefore increase R&D productivity.
Lucille Conroy, MBChB
Non Executive Director
Lucille Conroy is a Principal at Abingworth with more than 11 years of experience in the healthcare industry, spanning venture investing, strategy consulting, clinical practice, and academic research.
Previously, Lucille was an investor at F-Prime Capital where she was involved in a funding and formation of several companies, including Arvelle Therapeutics (acquired by Angelini for $960M). Before F-Prime, Lucille was a consultant with McKinsey & Company. Lucille served as a physician for a number of years at The National Hospital for Neurology and Neurosurgery, Imperial College and Barts Healthcare trusts.
Lucille holds degrees in Clinical Neuroscience and in Medicine with distinction from the University of Glasgow. She is a Member of the Royal College of Physicians in London.
Jonathan Tobin PhD, MBA
Non Executive Director
Jonathan is a Partner at Brandon Capital, based in London. In addition to Myricx Pharma, he serves on the boards of Brandon portfolio companies Pheon Therapeutics (an ADC company where Brandon co-led a $68m series A raise in March 2022), CatalYm, and NRG Therapeutics.
Jonathan has over 15 years’ experience in venture capital and technology commercialisation. Prior to joining Brandon in 2021, Jonathan was a Managing Director at Arix Bioscience, a UK and US-based biotech venture firm, where he sat on several boards including: Artios Pharma, Atox Bio, Depixus, STipe Therapeutics, and VelosBio (a clinical stage ADC company acquired by Merck in 2020 for $2.75 billion).
Prior to working at Arix, Jonathan spent five years at UK early-stage venture capital firm Touchstone Innovations as a Principal in the Healthcare Ventures team and was involved in creating several early stage companies, including Inivata, acquired by Neogenomics for $390m. He carried out postdoctoral research on cancer cell signalling at the Cancer Research UK London Research Institute (now the Francis Crick Institute).
Jonathan has a first class degree in Biology from the University of Oxford , a PhD in in genetic diseases from UCL, and an MBA with Distinction from Imperial College Business School.
Paolo Paoletti, MD
Non Executive Director
Paolo has 25+ years of experience in the life science sector. With a strong focus on oncology and precision medicine, he brings extensive experience in R&D and commercialisation in the pharma industry
Paolo was previously CEO at GammaDelta Therapeutics where he successfully led the development of the allogeneic cell therapy of Vδ1 gamma delta T cells through to clinical trials, before its acquisition by Takeda in 2022.
He was the first President of GSK Oncology and in eight years he brought seven new medicines to cancer patients, focusing on precision medicine. In a complex three-way transaction, the GSK Oncology Franchise was subsequently acquired by Novartis for $16bn in 2014.
Paolo also held former pharma roles with Eli Lilly and Company, including Vice President of Oncology Clinical Development.
Earlier in his career Paolo was in academia and served as Professor of Pulmonary Medicine at the University of Pisa. He is the author of more than 300 publications.
Paolo is currently a member of the Board of Genmab Therapeutics, where he is also the Chairman of the Scientific Committee, a member of the Investment Committee at Apollo Therapeutics and, Scientific Advisor to 3B Future Health Fund and Dawn Bio.
Paolo has a degree in medicine from the University of Pisa, Italy.
